Agenda

Session Introduction

Seth A. Wander, MD, PhD

‍

Novel Antiestrogen Agents and Dynamic ctDNA Monitoring for HR+/HER2- MBC

Katherine DiNardo, MD

‍

Targeting the PI3K Pathway: Rational Drug Design and New Strategies

Neil Iyengar, MD

‍

After Endocrine Resistance: Antibody Drug Conjugates for Metastatic HR+ Breast Cancer

Rebecca A. Shatsky, MD

‍

Audience Q&A and Panel Discussion

Seth A. Wander, MD, PhD; Katherine DiNardo, MD; Neil Iyengar, MD; Rebecca A. Shatsky, MD